1. Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease .
- Author
-
Hampel, Harald, Vergallo, Andrea, Afshar, Mohammad, Akman-Anderson, Leyla, Arenas, Joaquín, Benda, Norbert, Batrla, Richard, Broich, Karl, Caraci, Filippo, Cuello, A Claudio, Emanuele, Enzo, Haberkamp, Marion, Kiddle, Steven J, Lucía, Alejandro, Mapstone, Mark, Verdooner, Steven R, Woodcock, Janet, and Lista, Simone
- Subjects
Humans ,Alzheimer Disease ,Early Diagnosis ,Eligibility Determination ,Clinical Trials as Topic ,Biomarkers ,Precision Medicine ,Drug Development ,Alzheimer’s disease ,biomarker-drug codevelopment ,blood-based biomarker ,clinical trial ,context of use ,pathophysiology ,precision medicine ,predictive biomarker ,systems biology ,Alzheimer's disease ,Clinical Research ,Clinical Trials and Supportive Activities ,Aging ,Acquired Cognitive Impairment ,Brain Disorders ,Alzheimer's Disease ,Prevention ,Alzheimer's Disease including Alzheimer's Disease Related Dementias ,Neurodegenerative ,Dementia ,Neurosciences ,4.1 Discovery and preclinical testing of markers and technologies ,5.1 Pharmaceuticals ,Other Medical and Health Sciences ,Psychiatry - Abstract
Alzheimer's disease (AD)-a complex disease showing multiple pathomechanistic alterations-is triggered by nonlinear dynamic interactions of genetic/epigenetic and environmental risk factors, which, ultimately, converge into a biologically heterogeneous disease. To tackle the burden of AD during early preclinical stages, accessible blood-based biomarkers are currently being developed. Specifically, next-generation clinical trials are expected to integrate positive and negative predictive blood-based biomarkers into study designs to evaluate, at the individual level, target druggability and potential drug resistance mechanisms. In this scenario, systems biology holds promise to accelerate validation and qualification for clinical trial contexts of use-including proof-of-mechanism, patient selection, assessment of treatment efficacy and safety rates, and prognostic evaluation. Albeit in their infancy, systems biology-based approaches are poised to identify relevant AD "signatures" through multifactorial and interindividual variability, allowing us to decipher disease pathophysiology and etiology. Hopefully, innovative biomarker-drug codevelopment strategies will be the road ahead towards effective disease-modifying drugs. .
- Published
- 2019